{"groups":[{"description":"Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity","id":"FG000","title":"Treatment (Copanlisib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"18"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Other complicating disease"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Still on treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Never start protocol therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Ineligible"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"35"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"31"}],"type":"Eligible"},{"achievements":[{"groupId":"FG000","numSubjects":"30"}],"type":"Started Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"28"}],"type":"Eligible and Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"30"}],"type":"Mutation Status Confirmed"},{"achievements":[{"groupId":"FG000","numSubjects":"25"}],"type":"Eligible, Treated and Mutation Status Confirmed"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"35"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The PIK3CA mutations status was determined by a CLIA-approved assay performed in a NCI-MATCH approved laboratory for all patients in this arm. Mutation status was confirmed for 30 patients based on confirmation report as of August 1, 2019.","recruitmentDetails":"Subprotocol Z1F was activated on June 20, 2018. Thirty-five patients were enrolled between June 2018 and December 2018."}